LIGAND PHARMACEUTICALS (LGND) Fundamental Analysis & Valuation

NASDAQ:LGND • US53220K5048

Current stock price

223.24 USD
-1.85 (-0.82%)
At close:
223.24 USD
0 (0%)
After Hours:

This LGND fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. LGND Profitability Analysis

1.1 Basic Checks

  • LGND had positive earnings in the past year.
  • LGND had a positive operating cash flow in the past year.
  • In multiple years LGND reported negative net income over the last 5 years.
  • Each year in the past 5 years LGND had a positive operating cash flow.
LGND Yearly Net Income VS EBIT VS OCF VS FCFLGND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

  • LGND has a Return On Assets of 7.97%. This is amongst the best in the industry. LGND outperforms 89.01% of its industry peers.
  • With an excellent Return On Equity value of 12.23%, LGND belongs to the best of the industry, outperforming 86.39% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 2.45%, LGND belongs to the top of the industry, outperforming 80.10% of the companies in the same industry.
  • LGND had an Average Return On Invested Capital over the past 3 years of 1.82%. This is significantly below the industry average of 13.11%.
  • The last Return On Invested Capital (2.45%) for LGND is above the 3 year average (1.82%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.97%
ROE 12.23%
ROIC 2.45%
ROA(3y)4.72%
ROA(5y)2.84%
ROE(3y)6.4%
ROE(5y)4.11%
ROIC(3y)1.82%
ROIC(5y)2.16%
LGND Yearly ROA, ROE, ROICLGND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

1.3 Margins

  • With an excellent Profit Margin value of 46.42%, LGND belongs to the best of the industry, outperforming 96.86% of the companies in the same industry.
  • Looking at the Operating Margin, with a value of 17.61%, LGND belongs to the top of the industry, outperforming 86.39% of the companies in the same industry.
  • LGND's Operating Margin has improved in the last couple of years.
  • LGND has a better Gross Margin (94.57%) than 95.81% of its industry peers.
  • In the last couple of years the Gross Margin of LGND has grown nicely.
Industry RankSector Rank
OM 17.61%
PM (TTM) 46.42%
GM 94.57%
OM growth 3Y125.81%
OM growth 5Y30.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.97%
GM growth 5Y2.47%
LGND Yearly Profit, Operating, Gross MarginsLGND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 200 300 400 500

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. LGND Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so LGND is destroying value.
  • The number of shares outstanding for LGND has been increased compared to 1 year ago.
  • The number of shares outstanding for LGND has been increased compared to 5 years ago.
  • LGND has a worse debt/assets ratio than last year.
LGND Yearly Shares OutstandingLGND Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
LGND Yearly Total Debt VS Total AssetsLGND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 6.38 indicates that LGND is not in any danger for bankruptcy at the moment.
  • LGND has a better Altman-Z score (6.38) than 76.96% of its industry peers.
  • LGND has a debt to FCF ratio of 9.12. This is a negative value and a sign of low solvency as LGND would need 9.12 years to pay back of all of its debts.
  • LGND's Debt to FCF ratio of 9.12 is fine compared to the rest of the industry. LGND outperforms 79.06% of its industry peers.
  • A Debt/Equity ratio of 0.44 indicates that LGND is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.44, LGND is not doing good in the industry: 63.87% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 9.12
Altman-Z 6.38
ROIC/WACC0.27
WACC9.09%
LGND Yearly LT Debt VS Equity VS FCFLGND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 22.23 indicates that LGND has no problem at all paying its short term obligations.
  • The Current ratio of LGND (22.23) is better than 93.19% of its industry peers.
  • LGND has a Quick Ratio of 21.98. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of LGND (21.98) is better than 93.19% of its industry peers.
Industry RankSector Rank
Current Ratio 22.23
Quick Ratio 21.98
LGND Yearly Current Assets VS Current LiabilitesLGND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. LGND Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.81% over the past year.
  • LGND shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.06% yearly.
  • The Revenue has grown by 60.40% in the past year. This is a very strong growth!
  • The Revenue has been growing slightly by 7.54% on average over the past years.
EPS 1Y (TTM)40.81%
EPS 3Y23.39%
EPS 5Y12.06%
EPS Q2Q%59.06%
Revenue 1Y (TTM)60.4%
Revenue growth 3Y10.97%
Revenue growth 5Y7.54%
Sales Q2Q%39.37%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.98% on average over the next years. This is quite good.
  • LGND is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.58% yearly.
EPS Next Y19.24%
EPS Next 2Y21.59%
EPS Next 3Y24.36%
EPS Next 5Y12.98%
Revenue Next Year10.34%
Revenue Next 2Y14.55%
Revenue Next 3Y13.78%
Revenue Next 5Y13.58%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LGND Yearly Revenue VS EstimatesLGND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
LGND Yearly EPS VS EstimatesLGND Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

5

4. LGND Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 27.77, LGND can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Earnings ratio of LGND indicates a rather cheap valuation: LGND is cheaper than 80.10% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.53. LGND is around the same levels.
  • With a Price/Forward Earnings ratio of 23.29, LGND is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, LGND is valued a bit cheaper than 76.96% of the companies in the same industry.
  • LGND is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 37.95, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 27.77
Fwd PE 23.29
LGND Price Earnings VS Forward Price EarningsLGND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, LGND is valued a bit cheaper than the industry average as 76.44% of the companies are valued more expensively.
  • LGND's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. LGND is cheaper than 75.92% of the companies in the same industry.
Industry RankSector Rank
P/FCF 91.02
EV/EBITDA 44.98
LGND Per share dataLGND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of LGND may justify a higher PE ratio.
  • A more expensive valuation may be justified as LGND's earnings are expected to grow with 24.36% in the coming years.
PEG (NY)1.44
PEG (5Y)2.3
EPS Next 2Y21.59%
EPS Next 3Y24.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LGND Dividend Analysis

5.1 Amount

  • No dividends for LGND!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LGND Fundamentals: All Metrics, Ratios and Statistics

LIGAND PHARMACEUTICALS

NASDAQ:LGND (4/16/2026, 4:31:29 PM)

After market: 223.24 0 (0%)

223.24

-1.85 (-0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners105.43%
Inst Owner Change0%
Ins Owners1.83%
Ins Owner Change2.62%
Market Cap4.45B
Revenue(TTM)268.09M
Net Income(TTM)124.45M
Analysts86.67
Price Target250 (11.99%)
Short Float %7.69%
Short Ratio6.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)42.08%
Min EPS beat(2)26.84%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)25.53%
Min EPS beat(4)7.61%
Max EPS beat(4)57.31%
EPS beat(8)8
Avg EPS beat(8)27.71%
EPS beat(12)12
Avg EPS beat(12)54.84%
EPS beat(16)15
Avg EPS beat(16)61.79%
Revenue beat(2)2
Avg Revenue beat(2)25.06%
Min Revenue beat(2)5.23%
Max Revenue beat(2)44.89%
Revenue beat(4)4
Avg Revenue beat(4)17.85%
Min Revenue beat(4)5.23%
Max Revenue beat(4)44.89%
Revenue beat(8)8
Avg Revenue beat(8)17.07%
Revenue beat(12)12
Avg Revenue beat(12)15.78%
Revenue beat(16)14
Avg Revenue beat(16)16.03%
PT rev (1m)0.68%
PT rev (3m)0.68%
EPS NQ rev (1m)13.25%
EPS NQ rev (3m)5.45%
EPS NY rev (1m)12.9%
EPS NY rev (3m)13.93%
Revenue NQ rev (1m)1.05%
Revenue NQ rev (3m)-1.72%
Revenue NY rev (1m)0.87%
Revenue NY rev (3m)0.52%
Valuation
Industry RankSector Rank
PE 27.77
Fwd PE 23.29
P/S 16.6
P/FCF 91.02
P/OCF 90.18
P/B 4.38
P/tB 9.02
EV/EBITDA 44.98
EPS(TTM)8.04
EY3.6%
EPS(NY)9.59
Fwd EY4.29%
FCF(TTM)2.45
FCFY1.1%
OCF(TTM)2.48
OCFY1.11%
SpS13.44
BVpS51.01
TBVpS24.74
PEG (NY)1.44
PEG (5Y)2.3
Graham Number96.0644 (-56.97%)
Profitability
Industry RankSector Rank
ROA 7.97%
ROE 12.23%
ROCE 3.1%
ROIC 2.45%
ROICexc 4.72%
ROICexgc 14.03%
OM 17.61%
PM (TTM) 46.42%
GM 94.57%
FCFM 18.24%
ROA(3y)4.72%
ROA(5y)2.84%
ROE(3y)6.4%
ROE(5y)4.11%
ROIC(3y)1.82%
ROIC(5y)2.16%
ROICexc(3y)3.31%
ROICexc(5y)3.45%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.31%
ROCE(5y)2.73%
ROICexgc growth 3YN/A
ROICexgc growth 5Y2.34%
ROICexc growth 3Y108.05%
ROICexc growth 5Y42.36%
OM growth 3Y125.81%
OM growth 5Y30.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.97%
GM growth 5Y2.47%
F-Score5
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 9.12
Debt/EBITDA 5.51
Cap/Depr 1.34%
Cap/Sales 0.17%
Interest Coverage 147.04
Cash Conversion 60.96%
Profit Quality 39.3%
Current Ratio 22.23
Quick Ratio 21.98
Altman-Z 6.38
F-Score5
WACC9.09%
ROIC/WACC0.27
Cap/Depr(3y)60.81%
Cap/Depr(5y)46.88%
Cap/Sales(3y)16.73%
Cap/Sales(5y)12.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.81%
EPS 3Y23.39%
EPS 5Y12.06%
EPS Q2Q%59.06%
EPS Next Y19.24%
EPS Next 2Y21.59%
EPS Next 3Y24.36%
EPS Next 5Y12.98%
Revenue 1Y (TTM)60.4%
Revenue growth 3Y10.97%
Revenue growth 5Y7.54%
Sales Q2Q%39.37%
Revenue Next Year10.34%
Revenue Next 2Y14.55%
Revenue Next 3Y13.78%
Revenue Next 5Y13.58%
EBIT growth 1Y108.55%
EBIT growth 3Y150.57%
EBIT growth 5Y40.24%
EBIT Next Year212.26%
EBIT Next 3Y59.73%
EBIT Next 5Y45.87%
FCF growth 1Y-48.64%
FCF growth 3Y-25.86%
FCF growth 5Y-0.48%
OCF growth 1Y-49.14%
OCF growth 3Y-29%
OCF growth 5Y-2%

LIGAND PHARMACEUTICALS / LGND Fundamental Analysis FAQ

What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?

ChartMill assigns a fundamental rating of 6 / 10 to LGND.


What is the valuation status for LGND stock?

ChartMill assigns a valuation rating of 5 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.


Can you provide the profitability details for LIGAND PHARMACEUTICALS?

LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 8 / 10.


Can you provide the financial health for LGND stock?

The financial health rating of LIGAND PHARMACEUTICALS (LGND) is 6 / 10.


What is the earnings growth outlook for LIGAND PHARMACEUTICALS?

The Earnings per Share (EPS) of LIGAND PHARMACEUTICALS (LGND) is expected to grow by 19.24% in the next year.